Blackmores Institute

<h3>Key highlights</h3><ul><li>Bacopa monnieri is a traditional Ayurvedic herb with growing scientific support for its neuroprotective and cognitive-enhancing effects.</li><li>Its bioactive constituents – particularly bacosides – exert antioxidant, anti-inflammatory, anti-aggregatory, and synaptic-modulating actions.</li><li>While generally well tolerated, it is best taken with food to avoid mild gastrointestinal effects.</li></ul><h3> Introduction</h3>As global populations age, neurodegenerative diseases are becoming a major public health challenge.1 Alzheimer’s disease (AD), the most common cause of dementia, currently affects millions of adults and is projected to contribute to over 130 million dementia cases by 2050.2,3 Parkinson’s disease (PD), now recognised as the fastest-growing neurological condition, is expected to double in prevalence within the same timeframe.4 Both disorders significantly affect function, independence, and quality of life, placing substantial strain on individuals, families, and healthcare systems.3These escalating figures highlight the urgent need for preventive and supportive interventions that target the underlying biological processes of neurodegeneration. Bacopa monnieri, traditionally used as a cognitive tonic, is increasingly recognised for its neuroprotective actions that can contribute to healthy cognitive ageing.1,3,5<h3> Pathophysiology of AD and PD</h3>AD involves hallmark features including amyloid-β plaque deposition, tau-related neurofibrillary tangles, loss of cholinergic neurons, oxidative stress, mitochondrial impairment, and chronic neuroinflammation – all of which contribute to progressive memory loss and cognitive decline.6,7PD is primarily associated with the degeneration of dopaminergic neurons in the substantia nigra. Mitochondrial dysfunction, oxidative stress, microglial activation, monoamine oxidase-B (MAO-B) activity, and α-synuclein aggregation drive motor and cognitive symptoms.5<h3> Neuroprotective actions of Bacopa monnieri</h3>Bacopa monnieri exerts broad neuroprotective effects relevant to AD and PD, including antioxidant and anti-inflammatory activity, suppression of neurotoxic protein aggregation, enhanced synaptic plasticity, and modulation of neurotransmitter pathways (see Figure 1).7–10Key mechanisms include:<ol><li>Antioxidant and mitochondrial protection
 Bacopa lowers reactive oxygen species, stabilises mitochondria, reduces lipid peroxidation, and increases antioxidant enzyme activity. Together, these actions help protect neurons from oxidative stress and support synaptic integrity.11–13</li><li>Anti-inflammatory effects
 Chronic neuroinflammation contributes to neuronal loss in both AD and PD. Bacopa reduces pro-inflammatory cytokine activity and helps downregulate inflammatory signalling cascades.7,14,15</li><li>Anti-amyloid and anti-tau activity
 Preclinical data show that bacopa may reduce amyloid-β aggregation, decrease plaque burden, and modulate tau kinases. These actions directly target central drivers of AD pathology.5,7,11</li><li>Support for synaptic plasticity and neurogenesis
 Bacopa enhances synaptic remodelling, increases brain-derived neurotrophic factor (BDNF), and promotes hippocampal neurogenesis. These actions support learning, memory consolidation, and compensatory rewiring of neural circuits affected by AD and PD pathology.1,5,11</li><li>Neurotransmitter modulation
 Bacopa increases acetylcholine levels and inhibits acetylcholinesterase, supporting memory and attention. It also modulates serotonin, dopamine, and MAO-B activity, which may preserve dopaminergic function in PD and contribute to emotional regulation.5,7,11
</li><li><img src="https://images.contentstack.io/v3/assets/blt948bd74310fc0ad0/blt27b859ea40c8fbb5/69f2970861d51a214bdbf27f/bibacopafigure1schematicrepresentationofthemajorneuroprotectivemechanismsofbacopamonnieri7.jpg" alt="bibacopafigure1schematicrepresentationofthemajorneuroprotectivemechanismsofbacopamonnieri7.jpg" class="embedded-asset" /></li></ol>Figure 1: Key actions of bacopa in neurodegenerative disease8 For a deeper understanding of all the mechanisms involved, see appendix.<h3> Clinical application</h3>Standardised bacopa extracts have demonstrated improvement in memory, attention, and cognitive performance across multiple human trials.7,16–18 Benefits have been observed in older adults, individuals with mild cognitive impairment, and healthy participants experiencing cognitive demand or stress.10,18,19Early clinical evidence shows improvement in emotional function in individuals with PD, and improvement in orientation, attention, and language domains in those with AD and mild cognitive impairment.7,11,19,20<h3> Dosing and safety</h3>Doses used in clinical studies typically range from 300 - 600 mg daily of standardised extract (equivalent to 5 -10 g of the dried herb). Effects are often observed after 12 weeks of supplementation.8,21Bacopa is generally well-tolerated. Mild gastrointestinal symptoms are the most commonly reported adverse effects, typically mitigated when taken with food. Further high-quality studies are required to refine optimal dosing and validate safety, especially for pregnant and breastfeeding women.8,21<h3> Conclusion</h3>Bacopa monnieri demonstrates a broad neuroprotective profile encompassing antioxidant, anti-inflammatory, anti-amyloid, mitochondrial-supportive, and synaptic-enhancing actions. These mechanisms underpin its potential to support cognitive function across adulthood and complement therapeutic strategies for managing AD and PD. While further large-scale clinical trials are needed, existing evidence highlights bacopa as a promising, well-tolerated intervention for maintaining cognitive health and supporting healthy brain ageing.<a href="/resources/tools/bacopa-technical-explainer" target="_self" style="">For a full prescribing guide, view our Bacopa technical explainer.</a><h3> Appendix</h3>Table 1: Neuroprotective actions of Bacopa monnieri and their benefits in AD and PD pathophysiology<table><tbody><tr><th>Mechanism of Bacopa monnieri</th><th>Benefits in AD and PD pathophysiology</th></tr><tr><td>Antioxidant and reduction of reactive oxygen species (ROS)
 Increases superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx) and glutathione S-transferases (GSTs); reduces lipid peroxidation 1,2</td><td> • Helps counteract oxidative stress-induced neuronal damage, slowing synaptic loss and cognitive decline and supporting motor function 3-5 </td></tr><tr><td>Antiinflammatory effects
 Reduces microglial activation, nitric oxide synthase (iNOS) and proinflammatory cytokines (like TNF-α, IL-6, IL-17a)1,5</td><td> • Mitigates chronic neuroinflammatory processes that exacerbate amyloid-β and tau accumulation in AD, helping maintain the integrity of neuronal networks involved in memory 1,6
 • Suppresses neuroinflammation that drives progressive dopaminergic neurodegeneration, potentially slowing PD progression 5 </td></tr><tr><td>Cholinergic activity
 Increases cholinergic neurotransmission and inhibits acetylcholinesterase 1,3</td><td> • Enhances acetylcholine levels and cholinergic signalling, improving attention and memory in AD and PD 1,3,4 </td></tr><tr><td>Antiamyloid and antitau actions
 Reduces Aβ aggregation and plaque burden; modulates tau kinases such as GSK3β 1,6</td><td> • Reduces amyloid-β accumulation and tau hyperphosphorylation, directly targeting core pathological drivers of AD and helping maintain synaptic integrity 1,4,6 </td></tr><tr><td>Monoaminergic activity
 Modulates monoamines and inhibits monoamine oxidase B (MAO-B) 3,5</td><td> • Slows dopamine breakdown by inhibiting MAO-B and blocking conversion of MPTP to toxic MPP⁺. This can provide symptomatic and neuroprotective benefits in PD 3-5 </td></tr><tr><td>Anti-apoptotic and mitochondrial protection
 Increases Bcl2 (an anti-apoptotic protein) and preserves mitochondrial membrane potential 1,4,5</td><td> • Stabilises mitochondrial energy metabolism and prevents apoptosis in vulnerable neurons. This may slow cognitive deterioration in AD and help maintain striatal dopamine levels in PD 1,5,6 </td></tr><tr><td>Neurogenesis
 Enhances neurogenesis and synaptic plasticity by modulating BDNF pathways and microRNA levels 3,4,7</td><td> • Enhances synaptic remodelling and may stimulate hippocampal neurogenesis, supporting learning, memory consolidation, and compensating for AD-related synaptic loss 1,4
 • Promotes neuroplastic changes within striatal and cortical regions, helping to maintain functional motor and cognitive circuits affected by dopaminergic decline 4,5 </td></tr></tbody></table><h3> References</h3><ol><li>Bychowski M, Kwaśna J, Górski M, Załęska A, Kaźmierczyk I, Lenart K, et al. Recent Advances in Bacopa Monnieri Research: Neuroprotective Effects and Cognitive Decline Mitigation in Neurodegenerative Diseases with a Focus on Alzheimer’s and Parkinson’s Diseases. Qual Sport. 2024 Dec 8;35:56377.</li><li>ALNasser MN, Alboraiy GM, Alsowig EM, Alqattan FM. Cholinesterase Inhibitors from Plants and Their Potential in Alzheimer’s Treatment: Systematic Review. Brain Sci. 2025 Feb 19;15(2):215.</li><li>Wang Z yuan, Deng Y lu, Zhou T yuan, Liu Y, Cao Y. Effects of natural extracts in cognitive function of healthy adults: a systematic review and network meta-analysis. Front Pharmacol. 2025 Mar 27;16:1573034.</li><li>Dorsey ER, Sherer T, Okun MS, Bloem BR. The Emerging Evidence of the Parkinson Pandemic. Brundin P, Langston JW, Bloem BR, editors. J Park Dis. 2018 Dec 18;8(s1):S3–8.</li><li>Nishanth B, Vijayababu P, Kurian N. Bacopa monnieri Extract As a Neuroprotective and Cognitive Enhancement Agent. Int J Drug Discov Pharmacol. 2023 Dec 27;2(4):44–56.</li><li>Kulkarni, P. Bacopa monnieri (Brahmi): A potential treatment course for neurological disorders: Review. Int J Herb Med. 2021;9(4):10–8.</li><li>Abdul Manap AS, Vijayabalan S, Madhavan P, Chia YY, Arya A, Wong EH, et al. Bacopa monnieri , a Neuroprotective Lead in Alzheimer Disease: A Review on Its Properties, Mechanisms of Action, and Preclinical and Clinical Studies. Drug Target Insights. 2019 Jan;13:117739281986641.</li><li>Gościniak A, Stasiłowicz-Krzemień A, Szeląg M, Pawlak J, Skiera I, Kwiatkowska H, et al. Bacopa monnieri: Preclinical and Clinical Evidence of Neuroactive Effects, Safety of Use and the Search for Improved Bioavailability. Nutrients. 2025 June 5;17(11):1939.</li><li>Bhat BA, Almilaibary A, Mir RA, Aljarallah BM, Mir WR, Ahmad F, et al. Natural Therapeutics in Aid of Treating Alzheimer’s Disease: A Green Gateway Toward Ending Quest for Treating Neurological Disorders. Front Neurosci. 2022 May 16;16:884345.</li><li>Servello A, Leccese V, Ettorre E. Natural Products for Neurocognitive Disorders. Alzheimer’s Dis Drug Discov. 2020 Dec 18;Exon Publications:205–20.</li><li>Valotto Neto LJ, Reverete De Araujo M, Moretti Junior RC, Mendes Machado N, Joshi RK, Dos Santos Buglio D, et al. Investigating the Neuroprotective and Cognitive-Enhancing Effects of Bacopa monnieri: A Systematic Review Focused on Inflammation, Oxidative Stress, Mitochondrial Dysfunction, and Apoptosis. Antioxidants. 2024 Mar 25;13(4):393.</li><li>Sekhar VC, Viswanathan G, Baby S. Insights Into the Molecular Aspects of Neuroprotective Bacoside A and Bacopaside I. Curr Neuropharmacol. 2019 Apr 5;17(5):438–46.</li><li>Fatima U, Roy S, Ahmad S, Al-Keridis LA, Alshammari N, Adnan M, et al. Investigating neuroprotective roles of Bacopa monnieri extracts: Mechanistic insights and therapeutic implications. Biomed Pharmacother. 2022 Sept;153:113469.</li><li>Palollathil A, Najar MA, Amrutha S, Pervaje R, Modi PK, Prasad TSK. Bacopa monnieri confers neuroprotection by influencing signaling pathways associated with interleukin 4, 13 and extracellular matrix organization in Alzheimer’s disease: A proteomics-based perspective. Neurochem Int. 2024 Nov;180:105864.</li><li>Chougle S, Kumar D, Khan A, Zehra S, Ali̇ A. Treatment of Alzheimer’s disease by natural products. J Exp Clin Med. 2021 Aug 30;38(4):634–44.</li><li>Ansari F, Sohel M, Haidary MMH, Mostaq MS, Akter S, Nahar A, et al. Therapeutic potential of clinically proven natural products in the management of dementia. Heliyon. 2024 Mar;10(6):e27233.</li><li>Thawabteh AM, Ghanem AW, AbuMadi S, Thaher D, Jaghama W, Karaman D, et al. Promising Natural Remedies for Alzheimer’s Disease Therapy. Molecules. 2025 Feb 17;30(4):922.</li><li>Lorca C, Mulet M, Arévalo-Caro C, Sanchez MÁ, Perez A, Perrino M, et al. Plant-derived nootropics and human cognition: A systematic review. Crit Rev Food Sci Nutr. 2023 Aug 29;63(22):5521–45.</li><li>Mohamed Afsal A. Herbs for Cognitive Enhancement: Pharmacological Insights into Memory and Neuroprotection. Int J Res Appl Sci Eng Technol. 2025 May 31;13(5):5159–65.</li><li>Mathur D, Goyal K, Koul V, Anand A. The Molecular Links of Re-Emerging Therapy: A Review of Evidence of Brahmi (Bacopa monniera). Front Pharmacol [Internet]. 2016 Mar 4 [cited 2025 Nov 28];7. Available from: http://journal.frontiersin.org/Article/10.3389/fphar.2016.00044/abstract</li><li>Basheer A, Agarwal A, Mishra B, Gupta A, Padma Srivastava MV, Kirubakaran R, et al. Use of Bacopa monnieri in the Treatment of Dementia Due to Alzheimer Disease: Systematic Review of Randomized Controlled Trials. Interact J Med Res. 2022 Aug 1;11(2):e38542.</li></ol>

With the global prevalence of Alzheimer’s and Parkinson’s disease rising rapidly, healthcare professionals are increasingly seeking evidence-based strategies to support cognitive health. Bacopa monnieri, a traditional Ayurvedic herb, is gaining scientific attention for its neuroprotective properties and potential to mitigate key mechanisms driving neurodegenerative decline.

Recommended for you

Iron Absorption | Why form matters

Rethinking eye health in the digital age

From Traditional Medicine to Modern Therapeutics | Natural approaches to blood glucose control

Optimising magnesium prescribing